Analysis of prognostic factors in patients with Carcinoma of Uterine Cervix

Kim, Mi Sook; Cho, Chul Koo; Yoo, Seong Yul; Yun, Hyong Geun; Shim, Jae Won; Kim, Jae Yong

Abstract

PURPOSE: The authors conducted a retrospective analysis of patients with the carcinoma of uterine cervix treated with curative radiation therapy to evaluated the prognostic factors that would affect the results of the therapy and to get the critical ideas in determining more aggressive treatment schedule.
METHODS
AND MATERIALS: From January 1987 to December 1988, Four hundreds and sixty patients with uterine cervical carcinomas treated with radiotherapy at KCCH were registered to this retrospective study. One hundred and three patients were treated with external radiation therapy alone, and 357 patients were treated with external radiation followed by low dose rate intracavitary radiation therapy. He follow-up rate was 88% and median follow-up duration was 48 months.
RESULTS
The overall 5 year survival rate of the patients was 67.7%, and when classified by FIGO stages, 5 year survival rates were 81.2%, 76.3%, 73.1%, 50%, 52.3%, 11.5% for stages Ib, IIa, IIb, IIIa, IIIb, IVa respectively. Tumor size(p=0.0002), endocervical growth pattern(p=0.003), lymph node invasion(p=0.0001), mean hemoglobin level(p=0.0001), and pathologic cell type(p=0.0001) were significant prognostic factors and decrease in survival for young age patient group was marginally important(p=0.03).
CONCLUSION
Significant prognostic factors I the radiation therapy of the uterine cervical carcinoma were tumor size, growth pattern of tumor, lymph node invasion, pathologic cell type, hemoglobin level of patients during treatment and lower survival rate in young age group was obvious, too. Patients with large size tumor(> or =4cm), especially combined with endocervical growth patterns or advanced stages(III or more) need more aggressive treatment to improve the outcome of treatment. And positive feature of lymph node invasion affected the result of therapy, so improvement in the diagnostic and therapeutic trial is essential.